In early August, 19 companies, including one pharmaceutical company, made purchases.

Pharmaceutical Network Industry Dynamics: With the normalization of IPOs, in early August, 19 companies have made requisitions, the industry believes that the number of monthly issues may remain high.
among the 19 companies, including MeiChang New Materials, Feng shang Culture, Da Hongli, Kapi billion, Anke Innovation and other enterprises, as well as a pharmaceutical company - Shanghai Kaisai Biotechnology Co., Ltd.
according to the exchange announcement, Kaisai Bio on August 3, the public offering of 41.6682 million shares, the issue price of 133.45 yuan / share, a single account purchase limit of 7000 shares, the top purchase needs to match the market value of 70,000 yuan.
public information shows that Kaisai Biological Company was founded on November 24, 2000, is a synthetic biology and other disciplines based on the use of biological manufacturing technology, engaged in the development, production and sales of new bio-based materials of high-tech enterprises.
at present, the commercial production of Kesai bio-products focus on the polyamide industry chain, mainly bio-based polyamide and can be used in the production of bio-based polyamide core raw materials, including DC12 (laurel diacid), DC13 (Brazilian acid) and other biological long-chain binary acid products and bio-based dimethyl dihamita.
it is also worth mentioning that the company produces biological long-chain binary acid products in the global market for a long time in a dominant position.
company around the polyamide industry chain production of biological long-chain binary acid products, bio-based diamide and bio-based polyamide products, can be widely used in automobiles, electronic appliances, textiles, medicine, spices and other fields.
recently, the Securities and Futures Commission issued a statement that it agreed to the Application for IPO registration of Kaiser Bio-Tech.
and Kaiser Bio has successfully held an online roadshow on July 31st, further moving towards the launch.
the application for listing, Kaisai Bio intends to raise 4,699 million yuan for "Kaisai (Jinxiang) Biological Materials Co., Ltd. 40,000 tons / year biological law diacid project," "bio-based polyamide engineering technology research center," "Kasai (Usu) Biotechnology Co., Ltd. annual output of 30,000 tons of long-chain diacid and 20,000 tons of long-chain polyamide project.
According to financial data, according to financial data, between 2017 and 2019, Kaisai Bio realized operating income of RMB 1.363 billion, RMB1,757 million and RMB1,916 million, corresponding to net profit of RMB 333 million, RMB 466 million and RMB479 million, respectively, and net profit after deduction was RMB312 million, RMB434 million and RMB461 million. During the
reporting period, the proportion of biological long-chain binary acid income to the main business income was 99.62%, 99.70% and 99.56%, respectively.
in addition, during the reporting period, the research and development costs of Kaisai Bio were RMB64.5602 million, RMB86.338 million and RMB9015.95 million, respectively, and the cost increased;
it is understood that the company is engaged in business belongs to the bio-based synthetic materials manufacturing.
in recent years, relevant departments have also issued a series of policies to support the development of the bio-manufacturing industry.
for example, in 2015, the Ministry of Industry and Information Technology issued the "Industry Key Common Technology Development Guide" defined the key technologies related to bio-based diamine and bio-based polyamide industrialization, a series of new high-performance bio-based polyamide and applications, and identified as the priority development of the industry key common technologies; The "Bio-Industry Development Plan" points out that to accelerate the promotion of the biological industry as a pillar industry of the national economy, in 2017, the Ministry of Science and Technology's "13th Five-Year Plan" for biotechnology innovation set the goal: by 2020, improve the biotechnology standard system, cultivate a number of enterprises with significant innovation capabilities, and basically form a more complete biotechnology innovation system.
.